Insulin-Like Growth Factor Binding Protein 4 Fragments Provide Incremental Prognostic Information on Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction by Hjortebjerg, Rikke et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Insulin-Like Growth Factor Binding Protein 4 Fragments Provide Incremental
Prognostic Information on Cardiovascular Events in Patients With ST-Segment
Elevation Myocardial Infarction
Hjortebjerg, Rikke; Lindberg, Søren; Pedersen, Sune; Mogelvang, Rasmus; Jensen, Jan S;
Oxvig, Claus; Frystyk, Jan; Bjerre, Mette
Published in:
Journal of the American Heart Association
DOI:
10.1161/JAHA.116.005358
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Hjortebjerg, R., Lindberg, S., Pedersen, S., Mogelvang, R., Jensen, J. S., Oxvig, C., ... Bjerre, M. (2017). Insulin-
Like Growth Factor Binding Protein 4 Fragments Provide Incremental Prognostic Information on Cardiovascular
Events in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American Heart Association,
6(3), [e005358]. https://doi.org/10.1161/JAHA.116.005358
Download date: 03. Feb. 2020
Insulin-Like Growth Factor Binding Protein 4 Fragments Provide
Incremental Prognostic Information on Cardiovascular Events in
Patients With ST-Segment Elevation Myocardial Infarction
Rikke Hjortebjerg, MSc; Søren Lindberg, MD, PhD; Sune Pedersen, MD, PhD; Rasmus Mogelvang, MD, PhD; Jan S. Jensen, MD, PhD, DMSc;
Claus Oxvig, MSc, PhD; Jan Frystyk, MD, PhD, DMSc; Mette Bjerre, MSc, PhD
Background-—Fragments of insulin-like growth factor binding protein 4 (IGFBP-4) are potential new biomarkers for cardiac risk
assessment. The fragments are generated on speciﬁc cleavage by pregnancy-associated plasma protein-A, which exerts
proatherogenic activity. This study investigated the prognostic value of IGFBP-4 fragments in patients with ST-segment elevation
myocardial infarction.
Methods and Results-—We prospectively included 656 patients with ST-segment elevation myocardial infarction treated with
percutaneous coronary intervention from September 2006 to December 2008. Blood samples were drawn before percutaneous
coronary intervention, and levels of intact IGFBP-4 and N-terminal and C-terminal IGFBP-4 fragments were measured by speciﬁc
assays. End points were 5-year all-cause and cardiovascular mortality and the combined end point of major adverse cardiac events.
Prognostic potential was evaluated on top of a clinical model in terms of discrimination, calibration, and reclassiﬁcation analysis.
During follow-up, 166 patients experienced a major adverse cardiac event and 136 patients died, of whom 69 died from
cardiovascular causes. Both IGFBP-4 fragments were associated with all end points (P<0.001). After multivariable adjustments,
both N-terminal and C-terminal IGFBP-4 fragment levels remained associated with all end points, including cardiovascular mortality
with hazard ratios per doubling in protein concentration of 2.54 (95% CI 1.59–4.07; P<0.001) and 2.07 (95% CI 1.41–3.04;
P<0.001), respectively. Incorporation of IGFBP-4 fragments into a clinical model with 15 risk factors improved C-statistics and
model calibration and provided incremental prognostic contribution, as assessed by net reclassiﬁcation improvement and
integrated discrimination improvement.
Conclusions-—IGFBP-4 fragments are associated with increased risk of all-cause mortality, cardiovascular mortality, and major
adverse cardiac events in patients with ST-segment elevation myocardial infarction. ( J Am Heart Assoc. 2017;6:e005358. DOI:
10.1161/JAHA.116.005358.)
Key Words: biomarker • cardiovascular disease • insulin-like growth factor binding protein 4 • pregnancy-associated plasma
protein A • ST-segment elevation myocardial infarction
A n important objective of cardiovascular disease (CVD)research is to identify novel biomarkers to improve
stratiﬁcation of patients with excessive risk. Pregnancy-
associated plasma protein-A (PAPP-A) has been regarded a
candidate marker in CVD.1,2 PAPP-A is a metzincin metallo-
proteinase present in the circulation as well as within tissues,
where it reversibly adheres to cell surfaces.3 In 2001, PAPP-A
was shown to be ubiquitously present in eroded atheroscle-
rotic plaques, and circulating levels were elevated in patients
with acute coronary syndrome.1 It was later revealed,
however, that administration of unfractionated heparin to
patients results in an abrupt increase in PAPP-A
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concentrations, probably through displacement of cell sur-
face–tethered PAPP-A.4,5 Because heparin is part of the
standard initial treatment of patients with acute myocardial
infarction, samples from these patients are not suitable for
PAPP-A measurements.
The proteolytic activity of PAPP-A is directed primarily
toward insulin-like growth factor (IGF) binding protein 4
(IGFBP-4), which is a key regulator of IGF bioactivity.6–8 On
local PAPP-A–mediated cleavage of IGFBP-4, IGF accessibility
is increased in proximity to the IGF-1 receptor. IGF-1
stimulates cell proliferation and promotes macrophage acti-
vation, low-density lipoprotein uptake, and release of proin-
ﬂammatory cytokines, which likely facilitate atherogenesis
and plaque instability.9 The functional role of PAPP-A in the
process of plaque destabilization has been conﬁrmed in PAPP-
A transgenic and gene knockout mouse models,10,11 and
these ﬁndings further support a proatherogenic effect of
PAPP-A–mediated IGF-1 release.
It has been proposed that the PAPP-A–generated IGFBP-4
fragments may be reﬂective of PAPP-A enzymatic activity.
Circulating levels of total PAPP-A correlate with levels of N-
terminal IGFBP-4 (NT-IGFBP-4) and C-terminal IGFBP-4 (CT-
IGFBP-4)12; therefore, IGFBP-4 fragments released from the
atheromatous plaque could reﬂect plaque burden and thus
serve as markers of atherosclerosis.13 We recently veriﬁed that
circulating IGFBP-4 fragment levels are unaffected by heparin
treatment of patients with ST-segment elevation myocardial
infarction (STEMI),5 and no other medical therapies are known
to signiﬁcantly impinge IGFBP-4 fragment levels.
The aim of the present study was to examine the
association between PAPP-A–generated IGFBP-4 fragments
and risk of mortality and major adverse cardiac events (MACE)
in a cohort of patients with STEMI. The value of the IGFBP-4
fragments was compared with traditional cardiovascular risk
factors in terms of discrimination, calibration, and reclassiﬁ-
cation analysis.
Materials and Methods
Patients
A total of 656 patients with STEMI treated with primary
percutaneous coronary intervention at Gentofte University
Hospital, Denmark, were included from September 2006
through December 2008. Details of the study population have
been described previously.14 Inclusion criteria were onset of
STEMI symptoms, including chest pain lasting for >30 min-
utes and <12 hours, persistent ST-segment elevation of
≥2 mm in ≥2 contiguous precordial ECG leads or ≥1 mm in
≥2 contiguous limb ECG leads, and an increase in troponin I
(TnI) to >0.5 lg/L. All patients were pretreated with unfrac-
tionated heparin, and glycoprotein IIb/IIIa inhibitors were
administered at the discretion of the operator. Following the
percutaneous coronary intervention procedure, patients
received aspirin (75 mg/day), clopidogrel (75 mg/day for
12 months), cholesterol-lowering treatment (statins), and b-
receptor antagonists. Hypertension and hypercholesterolemia
were deﬁned as use of blood pressure–lowering or choles-
terol-lowering drugs, respectively, on admission. Patients
were considered to have diabetes mellitus if they received
glucose-lowering drugs on admission or had a fasting plasma
glucose level ≥7 mmol/L or a nonfasting level of
≥11.1 mmol/L. Multivessel disease was deﬁned as 2- or 3-
vessel disease and complex lesions such as type C lesions.
Advanced echocardiography was performed in 344 patients
(52%) at 1 to 3 days after admission using Vivid 7 or E9 (GE
Healthcare). Left ventricular ejection fraction (LVEF) was
obtained using the modiﬁed biplane Simpson method. Serum
and EDTA plasma were drawn from the femoral sheath at the
beginning of the percutaneous coronary intervention proce-
dure and stored at 80°C. The study was approved by the
local ethics committee and the Data Protection Agency and
complied with the Declaration of Helsinki. Informed consent
was obtained from all participants.
Follow-up and End Points
Patients were prospectively followed for 5 years through the
Danish Civil Registration system and the National Causes of
Death Registry, which offers information from physicians on
causes of death according to the International Classiﬁcation of
Diseases, 10th Revision (ICD-10).15 Follow-up information was
collected on all-cause mortality, death due to recorded
cardiovascular event, and occurrence of nonfatal MACE
deﬁned as readmission due to acute myocardial infarction,
ischemic stroke, or heart failure. Information on readmissions
was obtained from the highly validated National Patient
Registry using the ICD-10 codes.16 Information was obtained
for all patients, and all events were thoroughly validated using
medical records, including laboratory measurements, hospital
summaries, and operative reports.
Laboratory Measurements
Routine methods
High-sensitivity C-reactive protein was determined by a
nephelometric assay (Dade Behring), and creatinine was
assayed using standard laboratory methods. TnI levels were
determined at baseline and after 6 and 12 hours using the
Immulite 2500 STAT Troponin I immunoassay (Siemens
Healthcare). Later determinations were performed if deemed
necessary, and the highest obtained value was reported as
peak TnI. Estimated glomerular ﬁltration rate was calculated
using the Modiﬁcation of Diet in Renal Disease formula.17
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Intact IGFBP-4 and NT- and CT-IGFBP-4 fragments
EDTA plasma levels of IGFBP-4, CT-IGFBP-4, and NT-IGFBP-4
were measured in duplicate using in-house time-resolved
immunoﬂuorometric assays based on monoclonal antibodies
(mAb) and recombinant human (rh) calibrators generously
provided by HyTest Ltd. The assays were performed as recently
described.5 Intact IGFBP-4 was measured using coating mAb
IBP182 (4IGF4 IBP182) and detection mAb IBP144 (4IGF4EU
IBP144). mAb IBP3 (4IGF4 IBP3) and mAb IBP180 (4IGF4EU
IBP180) were used for the determination of the NT-IGFBP-4
fragment, and mAb IBP182 and mAb IBP163 (4IGF4EU IBP163)
were applied for the determination of the CT-IGFBP-4 fragment.
As calibrators, full-length rhIGFBP-4 (8IGF4), rhNT-IGFBP-4
(8NFB4), and rhCT-IGFBP-4 (8CIG4) were applied. In each
fragment assay, one of the antibodies speciﬁcally recognized
the proteolytic neoepitope generated on cleavage by PAPP-A.
Detection limits were 0.5 lg/L IGFBP-4, 0.4 lg/L CT-IGFBP-4,
and 0.9 lg/L NT-IGFBP-4. Intra- and interassay coefﬁcient of
variations (CVs) were <10% and <15%, respectively.
Statistical Analysis
Nonnormally distributed variables were log2-transformed prior
to statistical analyses. Frequency distribution of log2-NT- and
log2-CT-IGFBP-4 and ﬁtted normal curves are provided in
Figure S1. A combined end point including all events was used
for comparison of baseline characteristics. Patients with or
without events during follow-up were compared using the
Student t test or Mann–Whitney U statistics on continuous
variables, and the chi-square test on categorical variables. The
Bonferroni adjusted level of signiﬁcance was reported for
correlation coefﬁcients (r value). Receiver operating charac-
teristic (ROC) curves were used to analyze the prognostic
values of intact IGFBP-4, NT-IGFBP-4, CT-IGFBP-4, C-reactive
protein, and peak TnI. C-statistics between models were
compared by testing equality concordance using Mann–
Whitney U statistics.18 Kaplan–Meier survival curves were
performed for NT- and CT-IGFBP-4 quartiles, and incidence
distributions were compared using the log-rank test.
Model Building
Survival analyses were performed using Cox proportional
hazards models. All candidate confounder variables and blood
biomarkers (Table 1) were initially considered for the model,
as were all transformations and interactions between them. In
model 1, prespeciﬁed variables were included based on
traditional cardiovascular risk factors (age, sex, systolic blood
pressure, total cholesterol level, high-density lipoprotein level,
diabetes mellitus, and smoking status).19 Furthermore, a
criterion for inclusion in model 1 was minimization of the
Bayesian information criterion.20 The Bayesian information
criterion is a likelihood-based measure for which lower values
indicate better model ﬁt and in which a penalty is paid for an
increased number of variables. Finally, a covariate was
included if it changed the estimate measure of association
by >10%. A baseline clinical model was generated including all
variables selected for model 1 (age, sex, systolic blood
pressure, total cholesterol level, high-density lipoprotein,
diabetes mellitus, smoking status, estimated glomerular
ﬁltration rate, hypertensive treatment, hemoglobin, previous
acute myocardial infarction, multivessel coronary artery
disease, complex lesion, C-reactive protein, and peak TnI).
The clinical model was then extended by the log2-transformed
NT- or CT-IGFBP-4 variable, and results were reported as
hazard ratio (HR) and 95% CI. Accordingly, each unit increase
in NT- or CT-IGFBP-4 on the log2-scale corresponds to a
doubling in NT- or CT-IGFBP-4, respectively. Because LVEF
measurements were obtained in only 344 patients, model 1
was assessed with and without LVEF as a covariate. Body
mass index, hypercholesterolemia, low-density lipoprotein,
triglyceride, symptom-to-balloon time, and use of glycoprotein
IIb/IIIa inhibitor did not fulﬁll the criteria for inclusion but
were included in a second model (model 2) as an extension of
model 1. Hazard proportionality and linearity assumptions
were checked by log-log plots, ﬁtted survival curves, and
smoothed martingale and Schonenfeld residuals plots.21–23
Furthermore, because a large number of events occurred
within the ﬁrst 3 months after STEMI, survival analyses were
repeated using a 3-month end point.
Model Performances
The incremental value of adding log2-NT- or log2-CT-IGFBP-4
to the clinical model for predicting end points was evaluated.
Discriminatory abilities of the models were compared by
Harrell’s C and Somers’ D statistics for censored data using
the “somersd” module in Stata version 13 (StataCorp LP). For
calibration, the Royston modiﬁcation of Nagelkerke’s R2
statistic for proportional hazards models was used to assess
the explained variation by using 1000 bootstrap repetitions of
the whole data set through the “str2ph” module in Stata.24
The Groennesby and Borgan extension of the Hosmer–
Lemeshow goodness-of-ﬁt test was applied to assess how
well the predicted models ﬁtted the observed incidence
data.25 Well-calibrated models show no signiﬁcant differences
in the Hosmer–Lemeshow test results. The Akaike information
criterion and the Bayesian information criterion were calcu-
lated for each model. Lower values indicate a better model,
but no statistical test compares the Akaike information
criterion and Bayesian information criterion scores. Overall
goodness-of-ﬁt was evaluated by likelihood ratio test. Net
reclassiﬁcation improvement (NRI) and integrated discrimina-
tion improvement (IDI), as described by Pencina et al,26,27
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were used to evaluate improvements in risk predictions. NRI
compares the nested addition of a new variable to a reference
model, rewarding correct reclassiﬁcation and penalizing
incorrect reclassiﬁcation. Any upward movement in patients
experiencing an event implies improved classiﬁcation,
whereas a downward movement implies worse reclassiﬁca-
tion. The interpretation is opposite for patients who do not
experience an event. NRI was computed both as category-
based NRI and continuous NRI. Category-based NRI was
assessed by comparing the predicted 5-year risk of all-cause
Table 1. Baseline Characteristics
Characteristics Total (n=656) No Events (n=431) Events (n=225) P Value
Age, y 6312 6011 6912 <0.001
Male/female, n 484/172 324/107 160/65 0.261
BMI, kg/m2 26 (24; 29) 26 (24; 29) 26 (23; 29) 0.034
Diabetes mellitus, % 9.1 7.7 12.0 0.067
Current smoker, % 52.7 54.8 48.9 0.153
Hypercholesterolemia, % 19.4 17.2 23.6 0.049
Hypertension, % 33.8 28.8 43.6 <0.001
Blood glucose, mmol/L 8.3 (7.0; 9.9) 8.1 (7.0; 9.4) 8.7 (7.2; 11) <0.001
Hemoglobin, mmol/L 8.71.0 8.80.8 8.51.1 <0.001
Total cholesterol, mmol/L 4.81.1 4.91.1 4.61.2 <0.001
HDL cholesterol, mmol/L 1.30.4 1.30.3 1.30.4 0.111
LDL cholesterol, mmol/L 2.91.0 3.01.0 2.71.1 <0.001
Triglycerides, mmol/L 0.98 (0.69; 1.6) 0.98 (0.67; 1.6) 0.99 (0.73; 1.5) 0.926
Systolic blood pressure, mm Hg 13327 13526 12828 0.003
eGFR, mL/min/1.73 m2 7324 7821 6327 <0.001
Creatinine, lmol/L 91 (78; 109) 88 (76; 103) 101 (84; 133) <0.001
C-reactive protein, mg/L 3 (1; 9) 3 (1; 7) 5 (2; 16) <0.001
Peak troponin I, lg/L 90 (28; 244) 81.3 (28; 212) 117 (27; 281) 0.059
Left ventricular ejection fraction, %* 45.89.0 46.98.6 42.89.3 <0.001
Glycoprotein IIb/IIIa inhibitor, % 25.9 25.8 26.2 0.897
Symptom-to-balloon time, minute 195 (130; 323) 190 (123; 310) 230 (140; 355) 0.051
Multivessel disease, % 27.0 24.6 31.6 0.057
Culprit lesion, % 0.353
Left anterior descending artery 47.6 47.1 48.4
Circumflex artery 10.4 11.6 8.0
Right coronary artery 42.0 41.3 43.6
Complex lesion, % 50.9 48.3 56.0 0.060
Previous myocardial infarction, % 6.3 5.1 8.4 0.093
Died during follow-up, n 136 0 136
Died due to cardiovascular event, n 69 0 69
MACE during follow-up, n 166 0 166
IGFBP-4, lg/L 15370 14664 16479 0.002
NT-IGFBP-4, lg/L 132 (99; 185) 120 (94; 155) 182 (118; 264) <0.001
CT-IGFBP-4, lg/L 52 (34; 77) 45 (31; 66) 69 (46; 108) <0.001
Data are meanSD or median (25th percentile; 75th percentile). Categorical variables are indicated as numbers (n) or percentage (%) of patients. BMI indicates body mass index; CT, C-
terminal; eGFR, estimated glomerular ﬁltration rate; HDL, high-density lipoprotein; IGFBP-4, insulin-like growth factor binding protein 4; LDL, low-density lipoprotein; MACE, major adverse
cardiac event; NT, N-terminal.
*Left ventricular ejection fraction was available in only 344 patients (52%), of which 102 patients experienced an event.
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mortality, cardiovascular mortality, and MACE between mod-
els across risk categories of <5%, 5% to 10%, 10% to 20%, and
>20% risk. Because risk categories in STEMI have not been
deﬁned, thresholds were based on values suggested in
previous studies of CVD events.28,29 Conversely, the contin-
uous NRI counts the direction of change in risk for every
participant rather than the crossing of a threshold. The IDI is
independent of category thresholds and reﬂects the actual
extent of change and not merely the direction. NRI and IDI
were obtained using 1000 bootstrap repetitions through the
“incrisk” module in Stata.
Results are presented as meanSD for normally dis-
tributed data and median (25th percentile; 75th percentile) for
skewed data. C-statistics and HRs are presented with 95%
CIs. A 2-tailed P<0.05 was considered statistically signiﬁcant.
Data were analyzed using Stata software.
Results
Baseline data are presented in Table 1. Median follow-up of
patients was 5 years (range 9 days to 5 years), during which
225 patients (34.3%) suffered from all-cause mortality,
cardiovascular mortality, or MACE. A total of 136 patients
(20.7%) died, and among causes of deaths, cardiovascular
events were responsible in 69 patients (10.5%). In a large
number of patients, all-cause mortality (n=46), cardiovascular
mortality (n=41), or MACE (n=59) occurred within the ﬁrst
3 months after STEMI. Because of the high-quality Danish
registration system, no patients were lost to follow-up.
Patients with events had higher circulating levels of intact
IGFBP-4 as well as NT- and CT-IGFBP-4, and a strong positive
correlation was observed between concentrations of NT-
IGFBP-4 and CT-IGFBP-4 (r=0.83, P<0.001). IGFBP-4 fragment
levels correlated negatively with estimated glomerular ﬁltra-
tion rate (NT-IGFBP-4: r=0.56, P<0.001; CT-IGFBP-4:
r=0.50, P<0.001); therefore, increased fragment concentra-
tions were associated with reduced kidney function.6,30
IGFBP-4 fragment levels were not associated with sex,
diabetes mellitus, symptom-to-balloon time, culprit lesion
location or complexity, peak TnI level, hypercholesterolemia,
or use of glycoprotein IIb/IIIa inhibitors. LVEF did not
signiﬁcantly correlate with NT-IGFBP-4 (r=0.119, P=0.179)
or CT-IGFBP-4 (r=0.114, P=0.219).
C-statistics for NT- and CT-IGFBP-4 were signiﬁcantly
higher compared with peak TnI levels (P<0.001) and C-
reactive protein (P<0.05) for all end points (Figure 1 and
Table 2). Intact IGFBP-4 did not perform better than C-
reactive protein or peak TnI for any end point (data not
shown), and thus was not subjected to further analyses.
Kaplan–Meier survival curves for all-cause mortality, cardio-
vascular mortality, and MACE in patients stratiﬁed by NT- and
CT-IGFBP-4 quartiles are illustrated in Figure 2. The log-rank
analyses showed signiﬁcantly different incidence distributions
according to NT- and CT-IGFBP-4 quartiles (all P<0.001)
(Table 2).
Cox Regression and Survival
NT- and CT-IGFBP-4 were predictors of MACE and all-cause
and cardiovascular mortality as continuous variables (log2-NT-
IGFBP-4 and log2-CT-IGFBP-4) in both univariable and multi-
variable analyses (Table 3). After multivariable adjustments,
NT- and CT-IGFBP-4 fragment levels were associated with
cardiovascular mortality with HRs per doubling in protein
concentration of 2.54 (95% CI 1.59–4.07; P<0.001) and 2.07
(95% CI 1.41–3.04; P<0.001), respectively. The prognostic
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Figure 1. Receiver operating characteristic curves for CRP, peak TnI, NT-IGFBP-4 (A), and
CT-IGFBP-4 (B). The end point was cardiovascular mortality. CRP indicates C-reactive
protein; CT, C-terminal; IGFBP-4, insulin-like growth factor binding protein 4; NT, N-terminal;
ROC, receiver operating characteristic; TnI, troponin I.
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performances were not affected by inclusion of the covariates
(model 2) that did not fulﬁll the criteria for inclusion in model
1. In the subgroup of patients with LVEF measurements,
addition of LVEF to model 1 did not alter the prognostic
performance, and NT- and CT-IGFBP-4 remained signiﬁcantly
associated with all end points (P<0.001).
A large number of events occurred within the ﬁrst
3 months after the STEMI. To investigate the association
between NT- and CT-IGFBP-4 and early events, survival
analyses were also performed using 3 months as the end
point. In both univariable and multivariable analyses, NT- and
CT-IGFBP-4 were predictors of MACE and all-cause and
cardiovascular mortality at 3 months. After multivariable
adjustments (model 1), cardiovascular mortality HRs per
doubling in protein concentration of NT- or CT-IGFBP-4 were
1.97 (95% CI 1.48–2.61; P<0.001) and 1.70 (95% CI 1.35–
2.15; P<0.001), respectively. Adjusting for the variables in
model 2 resulted in HRs of 2.71 (95% CI 1.42–5.17; P<0.001)
for NT-IGFBP-4 and 2.07 (95% CI 1.23–3.48; P<0.001) for CT-
IGFBP-4.
Incremental Prognostic Value of IGFBP-4
Fragments Over Clinical Risk Factors
Table 4 shows the results of analysis using calibration,
discrimination, and reclassiﬁcation metrics to evaluate the
incremental usefulness of IGFBP-4 fragments over clinical risk
factors for the prediction of all-cause mortality, cardiovascular
mortality, and MACE. C-statistics for the prediction of all end
points signiﬁcantly increased when NT- or CT-IGFBP-4 was
added to the clinical model. For the prediction of cardiovas-
cular mortality, NT- and CT-IGFBP-4 provided signiﬁcant
discriminatory information with increases in C-statistics of
2.9% (0.38; 5.5%; P=0.025) and 2.7% (0.15; 5.3%; P=0.038),
respectively.
Nagelkerke’s R2 was higher for models extended by NT- or
CT-IGFBP-4. For nested models, R2 increases with the
strength of association, and thus higher R2 indicates better
calibration of a model. The P values for the Hosmer–
Lemeshow statistics signiﬁed that model-based estimates
aligned with observed outcomes. Akaike information criterion
and Bayesian information criterion were lower for all end
points in models containing NT- or CT-IGFBP-4. Global
goodness-of-ﬁt was better in models including NT- or CT-
IGFBP-4 than in the model with only established risk factors,
as evaluated by likelihood ratio tests.
Category NRI, continuous NRI, and IDI were calculated to
evaluate whether the addition of the IGFBP-4 fragments to the
clinical model led to any signiﬁcant risk reclassiﬁcation of the
end points. Continuous NRI and IDI were signiﬁcantly
increased for all end points after inclusion of either NT- or
CT-IGFBP-4. Consequently, participants were correctly
Table 2. C-Statistics and Log-Rank Analyses of All-Cause Mortality, Cardiovascular Mortality, and MACE
C-Statistics NT-IGFBP-4 CT-IGFBP-4 CRP Peak TnI
All-cause mortality 0.76 (0.72; 0.81)*,† 0.75 (0.70; 0.80)*,† 0.68 (0.63; 0.73) 0.55 (0.50; 0.61)
Cardiovascular
mortality
0.82 (0.77; 0.87)*,† 0.80 (0.75; 0.86)*,† 0.69 (0.62; 0.76) 0.57 (0.48; 0.65)
MACE 0.71 (0.67; 0.76)*,† 0.70 (0.66; 0.75)*,† 0.59 (0.54; 0.64) 0.54 (0.49; 0.60)
Log-Rank
NT-IGFBP-4 Quartiles
P Value1 (31.6–100.8 lg/L) 2 (100.9–132.6 lg/L) 3 (132.7–184.8 lg/L) 4 (184.9–810.1 lg/L)
Patients, n 164 164 164 164
All-cause mortality, n 12 17 31 76 <0.001
Cardiovascular mortality, n 1 8 12 48 <0.001
MACE, n 16 32 35 83 <0.001
CT-IGFBP-4 Quartiles
P Value1 (4.1–34.3 lg/L) 2 (34.4–52.0 lg/L) 3 (52.1–78.3 lg/L) 4 (78.4–348.8 lg/L)
Patients, n 164 164 164 164
All-cause mortality, n 12 16 36 72 <0.001
Cardiovascular mortality, n 4 6 14 45 <0.001
MACE, n 19 30 44 73 <0.001
C-statistics are reported individually for NT-IGFBP-4, CT-IGFBP-4, peak TnI, and CRP (mean and 95% CI). CRP, C-reactive protein; CT, C-terminal; IGFBP-4, insulin-like growth factor binding
protein 4; MACE, major adverse cardiac event; NT, N-terminal; TnI, Troponin I.
*P<0.001 when compared with peak TnI.
†P<0.05 when compared with CRP. Log-rank values are reported a numbers (n) of patients.
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reclassiﬁed both according to direction of change in risk and
actual extent of change. Category-based NRI using predeﬁned
risk categories of <5%, 5% to 10%, 10% to 20%, and >20% risk
was signiﬁcant for all end points after addition of NT-IGFBP-4
to the clinical model (95% CI did not contain zero). Of the 69
patients who died of CVD, 33.3% changed risk category when
NT-IGFBP-4 was included. Of these, 78.3% were correctly
reclassiﬁed to a higher risk category. Of the 587 patients not
suffering from cardiovascular mortality, 27.6% changed risk
category and 63.9% were correctly reclassiﬁed. The reclassi-
ﬁcation table of patients initially classiﬁed as having a 5-year
risk of cardiovascular mortality based on model 1 who were
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    31.6−100.8 µg/L  
    100.9−132.6 µg/L
    132.7−184.8 µg/L
    184.9−810.1 µg/L
0.0
0.2
0.4
0.6
0.8
Al
l−
ca
us
e 
m
or
ta
lit
y
0 1 2 3 4 5
Years of follow−up
CT−IGFBP−4
    4.1−34.3 µg/L    
    34.4−52.0 µg/L  
    52.1−78.3 µg/L  
    78.4−348.8 µg/L
0.0
0.2
0.4
0.6
0.8
Al
l−
ca
us
e 
m
or
ta
lit
y
0 1 2 3 4 5
Years of follow−up
0.0
0.2
0.4
0.6
0.8
Ca
rd
io
va
sc
ul
ar
 m
or
ta
lity
0 1 2 3 4 5
Years of follow−up
0.0
0.2
0.4
0.6
0.8
Ca
rd
io
va
sc
ul
ar
 m
or
ta
lity
0 1 2 3 4 5
Years of follow−up
0.0
0.2
0.4
0.6
0.8
M
AC
E
0 1 2 3 4 5
Years of follow−up
0.0
0.2
0.4
0.6
0.8
M
AC
E
0 1 2 3 4 5
Years of follow−up
BA
Figure 2. Risk of all-cause mortality, cardiovascular mortality, and MACE in patients
according to quartiles of NT-IGFBP-4 (A) and CT-IGFBP-4 (B). CT indicates C-terminal; IGFBP-
4, insulin-like growth factor binding protein 4; MACE, major adverse cardiac event; NT, N-
terminal.
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reclassiﬁed to a higher or lower risk category by the addition
of NT-IGFBP-4 is illustrated in Table S1. CT-IGFBP-4 signiﬁ-
cantly improved risk reclassiﬁcation for the prediction of
cardiovascular mortality but did not yield any improvements
for the prediction of all-cause mortality or MACE (95% CI
contained zero).
Discussion
The present study demonstrates that IGFBP-4 fragments are
associated with an increased risk of all-cause mortality,
cardiovascular mortality, and MACE in a cohort of patients
with STEMI. The associations were signiﬁcant both at
3 months and 5 years after the STEMI. Nevertheless, an
association alone is insufﬁcient to establish prognostic value,
and the use of IGFBP-4 fragments to determine the risk of a
future event as a continuous variable demands cautious
consideration. Various risk scores and statistical tests in the
cardiovascular area have generated considerable controversy,
and no clear consensus has been established. In this study,
the incremental prognostic value of the addition of the IGFBP-
4 fragments to the clinical model was assessed by discrim-
ination, calibration, and reclassiﬁcation analyses. Discrimina-
tion and calibration analyses indicated that models including
either NT- or CT-IGFBP-4 were more accurate than the clinical
model alone. To assess the magnitude of improvement rather
than testing the hypothesis that said improvement was
greater than zero, we computed category-based NRI, contin-
uous NRI, and IDI. Importantly, neither NT- nor CT-IGFBP-4
had negative overall NRI values, which are indicative of
worsened reclassiﬁcation. When assessing the true discrim-
inatory potential of a new biomarker in contrast to other risk
factors, and especially when making comparisons between
studies, continuous NRI may be the best metric. It yields the
incremental strength of the new biomarker after accounting
for correlations with variables included in the clinical model
and, unlike HRs, can be compared between studies of
biomarkers with different statistical distributions. Although
Table 3. Multivariable Cox Regression Analyses for All-Cause Mortality, Cardiovascular Mortality, and MACE at 5 Years
Model
All-Cause Mortality Cardiovascular Mortality MACE
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Log2-NT-IGFBP-4
All patients (n=656)
Univariable 3.33 (2.69–4.13) <0.001 4.36 (3.25–5.86) <0.001 2.71 (2.22–3.30) <0.001
Model 1 2.13 (1.53–2.97) <0.001 2.54 (1.59–4.07) <0.001 1.97 (1.48–2.61) <0.001
Model 2 2.19 (1.55–3.10) <0.001 2.70 (1.65–4.41) <0.001 1.93 (1.45–2.58) <0.001
Subgroup with LVEF (n=344)
Univariable 2.17 (1.47–3.21) <0.001 4.09 (2.08–8.03) <0.001 2.35 (1.74–3.18) <0.001
Model 1 1.75 (1.05–3.10) 0.031 2.62 (0.97–7.05) 0.057 1.66 (1.09–2.51) 0.017
Univariable plus LVEF 2.12 (1.42–3.15) <0.001 3.85 (1.93–7.67) <0.001 2.13 (1.57–2.89) <0.001
Model 1 plus LVEF 1.72 (1.02–3.09) 0.042 2.63 (1.01–7.05) 0.047 1.59 (1.03–2.45) 0.035
Log2-CT-IGFBP-4
All patients (n=656)
Univariable 2.78 (2.27–3.40) <0.001 3.69 (2.78–4.89) <0.001 2.38 (1.98–2.86) <0.001
Model 1 1.74 (1.33–2.29) <0.001 2.07 (1.41–3.04) <0.001 1.70 (1.35–2.15) <0.001
Model 2 1.78 (1.34–2.37) <0.001 2.13 (1.43–3.16) <0.001 1.70 (1.34–2.16) <0.001
Subgroup with LVEF (n=344)
Univariable 2.11 (1.49–2.97) <0.001 4.29 (2.23–8.25) <0.001 2.29 (1.73–3.03) <0.001
Model 1 1.79 (1.11–2.89) 0.016 3.63 (1.32–9.99) 0.012 1.65 (1.16–2.35) 0.006
Univariable plus LVEF 2.06 (1.46–2.92) <0.001 4.02 (2.07–7.82) <0.001 2.12 (1.60–2.79) <0.001
Model 1 plus LVEF 1.78 (1.10–2.87) 0.019 3.62 (1.31–9.95) 0.013 1.60 (1.11–2.29) 0.012
Model 1: age, sex, estimated glomerular ﬁltration rate, hypertension, high-density lipoprotein, total cholesterol, systolic blood pressure, hemoglobin, current smoking, diabetes, previous
acute myocardial infarction, multivessel coronary artery disease, complex lesion, C-reactive protein, and peak troponin I. Model 2: model 1 plus body mass index, hypercholesterolemia,
low-density lipoprotein, triglyceride, symptom-to-balloon time, and use of glycoprotein IIb/IIIa inhibitor. Separate analyses were performed on the subgroup of patients with LVEF
measurements (n=344). Results are reported as HR and 95% CI. One-unit increase in NT- or CT-IGFBP-4 on the log2-scale corresponds to a doubling in NT- or CT-IGFBP-4, respectively. CT
indicates C-terminal; HR, hazard ratio; IGFBP-4, insulin-like growth factor binding protein 4; LVEF, Left ventricular ejection fraction; MACE, major adverse cardiac event; NT, N-terminal.
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challenging, Pencina et al27 suggested interpretations of the
continuous NRI: NRI <0.2 is weak, NRI 0.4 is intermediate,
and NRI >0.6 can be considered strong. Continuous NRI in the
present study ranged between 0.33 and 0.40.
Biomarkers that mirror the degree and severity of the
plaque burden are especially interesting because they may
also be useful in syndromes such as unstable angina
pectoris, in which peak TnI and creatinine kinase–MB levels
are not elevated and ECG changes are often lacking or
inconclusive. The rationale for the use of IGFBP-4 fragments
as biomarkers for cardiac risk assessment is based on the
assumption that PAPP-A is actively involved in the develop-
ment of atherosclerosis.12,13 It has been suggested, how-
ever, that IGF-1 and PAPP-A may instead be cardioprotective
and increase as a compensatory mechanism attempting to
limit plaque progression and overall atherosclerotic bur-
den.31,32 Speaking against this theory, apolipoprotein E–
deﬁcient mice with a deletion of the PAPP-A gene and fed a
high-fat diet show an 80% reduction in plaque area, whereas
transgenic overexpression of PAPP-A accelerates plaque
progression.10,11,33 Moreover, PAPP-A substrate binding site
inhibition with a neutralizing monoclonal PAPP-A antibody
results in 70% reduction in atherosclerotic plaque develop-
ment in apolipoprotein E–deﬁcient mice.34 Accordingly,
PAPP-A seems to play an unfavorable functional role in
the process of plaque destabilization and may not only be a
marker of plaque vulnerability but also be indicative of poor
prognosis after the occurrence of a cardiovascular event.1,4
The use of the IGFBP-4 fragments as biomarkers is further
supported by a number of observations of which a few merit
particular attention. First, we recently showed that circulat-
ing levels of PAPP-A correlate with levels of NT- and CT-
IGFBP-4 fragments,12 and this was conﬁrmed in the present
study. Second, PAPP-A–dependent proteolysis of IGFBP-4 is
very speciﬁc, and the IGFBP-4 fragments do not undergo
further modiﬁcations or truncations in the circulation.35
Third, the IGFBP-4 fragments display great storage stabil-
ity.5,13 Fourth, treatment of patients with heparin promptly
increases circulating PAPP-A levels,4,12 whereas the 2
IGFBP-4 fragments are not affected. Thus, heparin may
displace cell-surface associated PAPP-A, but the overall
PAPP-A activity toward IGFBP-4 appears unaltered.5 To
reafﬁrm this ﬁnding in the present study, PAPP-A levels
were measured in 38 randomly selected patients, and levels
were signiﬁcantly higher in all patients (>20 ng/mL) com-
pared with non–heparin-treated participants (<2 ng/mL).12
Finally, active PAPP-A consists of 2 identical PAPP-A
subunits, whereas the inactive form is composed of 2
PAPP-A subunits covalently linked to 2 inhibitory subunits of
the proform of eosinophil major basic protein.7,36 PAPP-A
assays, however, generally lack the ability to discriminate
between the forms.37,38Ta
bl
e
4.
C
on
tin
ue
d
Pe
rf
or
m
an
ce
M
ea
su
re
s
Al
l-C
au
se
M
or
ta
lit
y
C
ar
di
ov
as
cu
la
r
M
or
ta
lit
y
M
AC
E
C
lin
ic
al
M
od
el
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-N
T-
IG
FB
P-
4
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-C
T-
IG
FB
P-
4
C
lin
ic
al
M
od
el
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-N
T-
IG
FB
P-
4
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-C
T-
IG
FB
P-
4
C
lin
ic
al
M
od
el
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-N
T-
IG
FB
P-
4
C
lin
ic
al
M
od
el
Pl
us
lo
g 2
-
C
T-
IG
FB
P-
4
ID
I(
95
%
CI
)
Ev
en
t
Re
fe
re
nc
e
0.
02
5
(0
.0
09
–0
.0
55
)
0.
02
2
(0
.0
05
–0
.0
50
)
Re
fe
re
nc
e
0.
02
7
(0
.0
03
–0
.0
69
)
0.
03
0
(0
.0
07
–0
.0
71
)
Re
fe
re
nc
e
0.
02
2
(0
.0
07
–0
.0
48
)
0.
02
0
(0
.0
06
–0
.0
44
)
No
ne
ve
nt
Re
fe
re
nc
e
0.
00
7
(0
.0
02
–0
.0
15
)
0.
00
5
(0
.0
01
–0
.0
13
)
Re
fe
re
nc
e
0.
00
2
(0
.0
00
–0
.0
08
)
0.
00
3
(0
.0
01
–0
.0
09
)
Re
fe
re
nc
e
0.
00
6
(0
.0
02
–0
.0
16
)
0.
00
7
(0
.0
02
–0
.0
15
)
Al
l
Re
fe
re
nc
e
0.
03
3
(0
.0
11
–0
.0
71
)
0.
02
7
(0
.0
06
–0
.0
63
)
Re
fe
re
nc
e
0.
02
9
(0
.0
04
–0
.0
77
)
0.
03
3
(0
.0
08
–0
.0
79
)
Re
fe
re
nc
e
0.
02
8
(0
.0
09
–0
.0
63
)
0.
02
7
(0
.0
08
–0
.0
59
)
A
cl
in
ic
al
m
od
el
w
as
ge
ne
ra
te
d
ba
se
d
on
va
ria
bl
es
se
le
ct
ed
fo
r
m
od
el
1
(a
ge
,s
ex
,e
st
im
at
ed
gl
om
er
ul
ar
ﬁ
ltr
at
io
n
ra
te
,h
yp
er
te
ns
io
n,
hi
gh
-d
en
si
ty
lip
op
ro
te
in
,t
ot
al
ch
ol
es
te
ro
l,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
,h
em
og
lo
bi
n,
cu
rr
en
t
sm
ok
in
g,
di
ab
et
es
,
pr
ev
io
us
ac
ut
e
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
m
ul
tiv
es
se
lc
or
on
ar
y
ar
te
ry
di
se
as
e,
co
m
pl
ex
le
si
on
,C
-r
ea
ct
iv
e
pr
ot
ei
n,
an
d
pe
ak
tr
op
on
in
I).
Th
e
ba
se
lin
e
m
od
el
w
as
th
en
ex
te
nd
ed
by
th
e
lo
g 2
-t
ra
ns
fo
rm
ed
N
T-
or
C
T-
IG
FB
P-
4
va
ria
bl
e.
Fo
r
ca
te
go
ry
N
RI
,
pa
tie
nt
s
w
er
e
di
vi
de
d
in
to
ris
k
ca
te
go
rie
s
(<
5%
,5
–1
0%
,
10
–2
0%
,
an
d
>
20
%
)
an
d
re
cl
as
si
ﬁ
ed
.
AI
C
in
di
ca
te
s
Ak
ai
ke
in
fo
rm
at
io
n
cr
ite
rio
n;
BI
C
,
Ba
ye
si
an
in
fo
rm
at
io
n
cr
ite
rio
n;
C
T,
C
-t
er
m
in
al
;
H
-L
,H
os
m
er
–L
em
es
ho
w
;
ID
I,
in
te
gr
at
ed
di
sc
rim
in
at
io
n
im
pr
ov
em
en
t;
IG
FB
P-
4,
in
su
lin
-li
ke
gr
ow
th
fa
ct
or
bi
nd
in
g
pr
ot
ei
n
4;
M
AC
E,
m
aj
or
ad
ve
rs
e
ca
rd
ia
c
ev
en
t;
N
RI
,n
et
re
cl
as
si
ﬁ
ca
tio
n
im
pr
ov
em
en
t;
N
T,
N
-t
er
m
in
al
.
DOI: 10.1161/JAHA.116.005358 Journal of the American Heart Association 10
IGFBP-4 Fragment Markers of Cardiovascular Events Hjortebjerg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 10, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
So far, studies of IGFBP-4 fragments as cardiac risk
markers in patients have provided conﬂicting results. In a
study by Schulz et al,39 NT- and CT-IGFBP-4 failed to predict
long-term outcome in patients with stable CVD, whereas
Postnikov et al13 showed strong associations between the
fragments and short-term cardiac events in patients with
acute myocardial infarction. It has been proposed that the
prognostic value might depend on whether patients present
with acute or stable disease, and it is intuitive to speculate
that IGFBP-4 fragment levels merely recapitulate infarct size
and the acute situation. However, we recently demonstrated
that NT- and CT-IGFBP-4 levels were not altered during the
acute phase of a myocardial infarction,5 and the fragments
predicted cardiovascular mortality in type 1 diabetes patients
without CVD at baseline during 12 years of follow-up.12 These
observations suggest that the discrepancies cannot solely be
explained by acute versus stable disease or short versus long
follow-up. We speculate that the different outcomes relate to
differences in study populations. It is worth mentioning that in
neither this nor previous studies did we ﬁnd an association
between the NT- or CT-IGFBP-4 fragments and LVEF, peak TnI,
location and complexity of the culprit lesion, symptom-to-
balloon time, or the use of statins and antiplatelet agents,
such as glycoprotein IIb/IIIa and cyclooxygenase inhibi-
tors.5,12
Although our ﬁndings are interesting and potentially
clinically relevant, the speciﬁc mechanisms in STEMI patients
are elusive and warrant further investigation. Furthermore, we
acknowledge that the value and utility of biomarkers in STEMI
patients is limited compared with other CVDs. One could
argue that the IGFBP-4 fragments may be more useful for risk
stratiﬁcation of patients with unstable angina or non-STEMI.
Instead, the potential purpose of a biomarker in STEMI may be
to provide long-term prognostication in patients at hospital
discharge in the hope of optimizing treatment management.
Considering this perspective, the present ﬁndings suggest
that the prognostic value of the IGFBP-4 fragments may be
complementary to other risk factors and improve clinical
decision making. However, our results cannot necessarily be
extrapolated to other patient cohorts, and clinical adoption
should await further validation of the ability of the biomarkers
to advise therapy that improves patient outcomes.
Study Strengths and Limitations
The cohort size and the follow-up period resulted in a large
number of events, which allowed for extensive adjustment. As
for study limitations, samples were collected only at baseline
and not throughout the follow-up period; therefore, we were
unable to evaluate changes in variables over time. The study
was entirely observational and yielded no evidence of
causality. Unfortunately, LVEF measurements were not
obtained for all patients and would have strengthened the
analyses. Finally, comparisons with additional relevant
biomarkers, such as B-type natriuretic peptide, were not
incorporated into the design and are beyond the scope of this
study.
Conclusions
Elevated levels of PAPP-A–generated IGFBP-4 fragments are
signiﬁcantly associated with increased risk of all-cause
mortality, cardiovascular mortality, and MACE in patients
with STEMI. Especially with regard to cardiovascular mortality,
the IGFBP-4 fragments possess incremental prognostic value
beyond that of conventional clinical risk factors.
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Table S1. Reclassification table comparing 5-year risk of cardiovascular mortality before and after 
addition of NT-IGFBP-4 to the clinical model. 
Patients were divided into risk categories (<5%, 5-10%, 10-20% and >20%) and classified using a clinical 
model (age, sex, eGFR, hypertension, HDL, total cholesterol, systolic blood pressure, haemoglobin, current 
smoking, diabetes, previous AMI, multivessel coronary artery disease, complex lesion, CRP and peak TnI) 
with and without the addition of NT-IGFBP-4. Total NRI was the sum of NRI in patients with and without 
events, using the calculation: ((number of events classified upwards) + (number of events classified 
downwards))/total number of events + ((number of non-events classified downwards) + (number of non-
events classified upwards))/total number of non-events. Light gray: improved classification, white: no 
classification change, dark gray: worse classification.  
AMI, acute myocardial infarction; CRP, C-reactive protein; CT, C-terminal; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; NRI, net reclassification improvement; NT-IGFBP, N-terminal 
insulin-like growth factor binding protein; TnI, Troponin I. 
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 Risk classification using 
clinical model 
Risk classification using 
clinical model + log2-NT-IGFBP-4 
Reclassified NRI 
 <5% 5-10% 10-20% >20% Total   
Patients with events (n)  
<5% 7 5 0 0 12 +5 
13/69 = 
0.188 
5-10% 1 5 5 0 11 +4 
10-20% 0 1 5 8 14 +7 
>20% 0 1 2 29 32 -3 
Total 8 12 12 37 69 +13 
Patients without events (n)   
<5% 285 19 1 0 305 -20 
56/587 = 
0.095 
5-10% 65 50 18 4 137 +43 
10-20% 5 24 44 11 84 +18 
>20% 0 2 13 46 46 +15 
Total 355 95 76 61 587 +56 
Total NRI 0.284  by guest on January 10, 2018
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Figure S1. Frequency distribution of log2-NT- and log2-CT-IGFBP-4 and fitted normal curves. 
Frequency distributions of log2-NT- and log2-CT-IGFBP-4 in the 431 patients without events (black circles) 
and the 255 patients with events (gray circles), along with the fitted normal curves (black). The vertical lines 
mark the mean protein levels. CT, C-terminal; IGFBP, insulin-like growth factor binding protein; NT, N-
terminal. 
 
 
 by guest on January 10, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Jan Frystyk and Mette Bjerre
Rikke Hjortebjerg, Søren Lindberg, Sune Pedersen, Rasmus Mogelvang, Jan S. Jensen, Claus Oxvig,
Infarction
Segment Elevation Myocardial−Information on Cardiovascular Events in Patients With ST
 Like Growth Factor Binding Protein 4 Fragments Provide Incremental Prognostic−Insulin
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.116.005358
2017;6:e005358; originally published March 17, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/3/e005358
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on January 10, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
